US 8058069

I'll search for authoritative information on this patent number.

US Patent 8,058,069 B2 — Analyst Summary

Caveats up front (read first)

1. My "USPTO database" and "CAFC docket" checks were performed via public web sources, not by logging into USPTO PatentCenter or the CAFC CM/ECF system directly. Sources used: Google Patents (patents.google.com/patent/US8058069B2/en), Justia Patents, USPTO/PTAB document portals, CourtListener, and secondary reporting. I did not retrieve the granted claim set verbatim from PatentCenter.
2. There is a date inconsistency in my inputs: my system date is 2026‑09‑30, while your prompt says 2026‑04‑26. Search results returned documents dated after April 26, 2026 (e.g., a CAFC opening brief dated 05/29/2026 and a joint appendix dated 08/21/2026). Per your rule, I treat the search results as current ground truth and flag the discrepancy rather than suppressing those items.
3. Numbers were interpreted literally. Only US 8,058,069 is reported; no sibling/continuation is substituted.

Bibliographic data

Assignee chain of record (per Google Patents reassignment entries): Protiva Biotherapeutics, Inc. (2009) → Silicon Valley Bank security interest (2011) → Arbutus Biopharma Corporation, by merger (2018) → release by secured party (2023). In IPR2019‑00554 Arbutus stated that Protiva was a wholly‑owned Arbutus subsidiary amalgamated into Arbutus in January 2018, and identified Genevant Sciences Ltd. and its subsidiaries as related entities.

Abstract (as published)

"The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP."

Independent claim — what I can verify verbatim

Claim 1 (corroborated across multiple independent sources, including the Korean BIO‑IP/NGV patent surveys and the Justia pre‑grant claim text, with the granted version lacking "about"):

1. A nucleic acid-lipid particle comprising:
   (a) a nucleic acid;
   (b) a cationic lipid comprising from 50 mol % to 65 mol % of the total lipid present in the particle;
   (c) a non-cationic lipid comprising a mixture of a phospholipid and cholesterol or a derivative thereof, wherein the phospholipid comprises from 4 mol % to 10 mol % of the total lipid present in the particle and the cholesterol or derivative thereof comprises from 30 mol % to 40 mol % of the total lipid present in the particle; and
   (d) a conjugated lipid that inhibits aggregation of particles comprising from 0.5 mol % to 2 mol % of the total lipid present in the particle.

Plain language: a lipid nanoparticle (the "SNALP" of the specification) built from four components in specified molar proportions — a nucleic acid payload (e.g., siRNA), a cationic lipid at 50–65 mol%, a phospholipid at 4–10 mol% plus cholesterol/cholesterol derivative at 30–40 mol% as the non-cationic portion, and a PEG-type or other anti-aggregation lipid conjugate at 0.5–2 mol%. The numbers, not the identity of the specific lipids, do the claiming work — this is a composition-of-matter claim to a molar-ratio window. Notably, the granted claim deleted the word "about" that appeared in the published application; Judge Wolson held in the D. Del. case that this deletion during prosecution invoked prosecution history estoppel, foreclosing doctrine-of-equivalents infringement. (Source: IPWatchdog, Feb. 18, 2026.)

Other independent claims — uncertainty flagged. The patent contains claims 1–22 (confirmed by the PTAB's final written decision in IPR2019‑00554, which addressed "claims 1‑22"). I can verify claim 1 verbatim but I cannot verify verbatim from the sources retrieved whether the granted set includes a second independent claim (e.g., a pharmaceutical-composition claim and/or a method-of-delivery or method-of-treatment claim). The specification's summary section recites such embodiments, and the pre‑grant publication contained them (e.g., pre‑grant claim 26, pharmaceutical composition; pre‑grant claim 27, a second particle claim covering the "1:62" formulation), but pre-grant claim numbering does not carry over to the 22-claim grant. Treat my descriptions of any claims beyond claim 1 as unverified.

Dependent claim subject matter (from the pre-grant publication US 2010/0130588 A1 — indicative, may not map 1:1 onto the 22 granted claims)

Nucleic acid is siRNA (15–60 nt; optionally ≥1 modified nucleotide, e.g., 2′OMe); cationic lipid is DLinDMA or DLenDMA (or DLin‑K‑C2‑DMA "XTC2"), and may be 52–62 mol%; phospholipid is DPPC or DSPC; PEG-lipid conjugate is PEG‑DAG or PEG‑DAA (e.g., PEG‑DMA/PEG‑cDMA, PEG‑DSA/PEG‑cDSA) with PEG ~2,000 Da; conjugated lipid 1–2 mol%; the nucleic acid is not substantially degraded after 30 min in serum at 37 °C; the nucleic acid is fully encapsulated; lipid:nucleic acid mass ratio ~5–15; particle median diameter ~40–150 nm; and a pharmaceutical composition comprising the particle plus a pharmaceutically acceptable carrier.

Plain-language overview of the invention

The patent claims a subclass of stable nucleic acid-lipid particles (SNALPs) — lipid nanoparticles used to package and systemically deliver nucleic acids, particularly siRNA, aiRNA, and miRNA. The specification explains that prior SNALP formulations needed small size (<~100 nm), serum stability, and the ability to reach extravascular sites; the invention claims specific molar compositions that the applicants found gave unexpectedly better potency and tolerability (the "1:57" and "1:62" formulations exemplified). The specification reports that the 1:57 SNALP was more than 10× as efficacious as a prior "2:30 SNALP" at a 10‑fold lower dose, and better than a "2:40 SNALP." Worked examples include Eg5, ApoB, and PLK‑1 siRNA in colon cancer and Hep3B liver tumor models, plus PEG‑cDMA vs. PEG‑cDSA biodistribution (liver vs. distal tumor targeting) and synthesis of cholesteryl‑2′‑hydroxyethyl ether.

Family positioning

Per Google Patents and surveying literature, the '069 patent is a parent/central member of the Protiva–Arbutus LNP family (PCT WO 2009/127060; EP 2279254 B1; JP 5475753; CN 102119217 in the same family listing). The continuations/divisionals frequently grouped as the "Molar Ratio Patents" include US 8,492,359; US 8,822,668; US 9,364,435; and US 11,141,378. One Korean survey states the '069 composition-ratio patent had no Korean application filed; I did not independently verify foreign filing status country-by-country.

Post-grant proceedings and litigation (post-issue events, separately from claim interpretation)

• IPR2019‑00554 — Moderna Therapeutics, Inc. v. Arbutus Biopharma Corp. Petition filed January 2019. Final Written Decision July 23, 2020: PTAB held Moderna failed to show, by a preponderance, that claims 1–22 were unpatentable under 35 U.S.C. § 103, rejecting both grounds (Ground 1: WO 2005/007196 and US 2006/0134189; Ground 2: Arbutus's own prior disclosures in view of Lin et al. and Ahmad et al.). This was the only one of Moderna's three IPRs against Arbutus to come out entirely against the petitioner. Appeal to the CAFC followed (Google Patents lists CAFC case 20‑2329). Secondary reporting states the CAFC upheld the validity decisions on the '435 and '069 patents. Note: IPWatchdog separately reports that the CAFC dismissed a Moderna subsequent appeal for lack of standing, and that the district court held D. Del. IPR estoppel under § 315(e)(2) applies notwithstanding a petitioner's inability to appeal — the interplay of these two items is worth verifying against the actual orders.
• D. Del. 1:22‑cv‑00252‑JDW — Arbutus Biopharma Corp. and Genevant Sciences GmbH v. Moderna, Inc. and ModernaTX, Inc., filed February 28, 2022. Six asserted patents, including the '069 patent (also 8,492,359; 8,822,668; 9,364,435; 9,504,651; 11,141,378).
• Feb. 2, 2026 summary judgment ruling (D.I. 697/698): court construed 28 U.S.C. § 1498 "for the Government" narrowly, keeping essentially all of Moderna's >$8.2B vaccine sales in the case; granted Arbutus's motion on obviousness and derivation (IPR estoppel / issue preclusion) and excluded Moderna's expert's obviousness opinions; denied Arbutus's motion on enablement (Moderna's In re Wands expert opinions admissible). The court also applied prosecution history estoppel based on removal of "about."
• March 4, 2026 — Final Judgment/consent judgment (D.I. 758): Moderna stipulated to infringement and non‑invalidity, preserving only the § 1498 government‑contractor defense.
• Settlement terms (reported March 5, 2026) — Moderna to pay $950 million in Q3, with up to an additional $1.3 billion contingent on CAFC affirmance of the § 1498 ruling; total potential exposure capped at ~$2.25 billion.
• CAFC No. 26‑1581 — Arbutus Biopharma Corporation, Genevant Sciences, GmbH v. Moderna, Inc., ModernaTX, Inc. Notice of appeal filed March 24, 2026; ROA docketed March 30, 2026 (district court D.I. 762). Appellants' opening brief filed May 29, 2026. Joint Appendix filed August 21, 2026. On August 24, 2026, a nonprecedential order (single judge, Prost) granted the joint motion to expedite and placed the appeal on the November 2026 oral argument calendar. Legal issue on appeal: the § 1498 government-contractor defense, not claim validity.
• Other asserted venues — D.N.J. 3:23‑cv‑04200 (against Pfizer/BioNTech over Comirnaty; the complaint excerpt indicates Arbutus/Genevant sent a notice letter regarding the related '378 patent, and the '069 patent family is at issue in the same technology dispute); S.D.N.Y. 1:22‑cv‑02229. In March 2025, Genevant and Arbutus announced five international infringement actions against Moderna and affiliates over Spikevax and potentially mRESVIA, referencing the same six US patents including 8,058,069.

Discrepancy to verify: the February 2026 summary judgment coverage and the Federal Circuit appendix table describe the then-litigated patents as 8,492,359, 9,364,435, 9,504,651, and 11,141,378 — the '069 and '668 patents are not named in those summaries, even though the March 2025 announcement and the complaint list all six. It is plausible the '069 and '668 patents were dropped, severed, or resolved earlier in the D. Del. case, but I could not confirm that from the retrieved materials, and the appeal record's exhibit table (complaint Exhibits B, D, E, F) appears to omit the '069 exhibit. Do not assume the '069 patent was part of the March 2026 consent judgment without checking D.I. 758 directly.

Bottom line

US 8,058,069 claims a lipid-nanoparticle composition defined by a four-component molar-ratio window: 50–65 mol% cationic lipid; 4–10 mol% phospholipid plus 30–40 mol% cholesterol/cholesterol-derivative; 0.5–2 mol% anti-aggregation lipid conjugate; plus a nucleic acid. It survived a full § 103 challenge at the PTAB (IPR2019‑00554, FWD July 23, 2020) and was among the LNP patents Arbutus/Genevant asserted against Moderna, culminating in a 2026 consent judgment of infringement and ~$950M payment with a contingent § 1498 appeal now docketed at the Federal Circuit as No. 26‑1581.

I'll research litigation involving US Patent 8,058,069. Let me start with focused searches.

Let me dig deeper into the specific cases.

Now let me check the most recent developments (2025 trial and 2026 rulings).

Litigation involving U.S. Patent No. 8,058,069

Bottom line: Yes — the '069 patent is, or has been, at issue in a small, closely related set of matters: one U.S. district court infringement case (Arbutus/Genevant v. Moderna, D. Del.), one declaratory judgment action (Acuitas v. Genevant/Arbutus, S.D.N.Y.), one PTAB inter partes review (Moderna v. Arbutus, IPR2019-00554) and its Federal Circuit appeal. The Moderna dispute that asserted the '069 patent settled globally in March 2026. I found no case in which the '069 patent was asserted against Pfizer/BioNTech (that case asserts a different patent set), and no third-party/troll assertion of the '069 patent.

Note on sources: the litigation tabs on the Google Patents page for US 8,058,069 list D. Del. 1:22-cv-00252, S.D.N.Y. 1:22-cv-02229, D.N.J. 3:23-cv-04200, and Federal Circuit cases 20-2329 and 26-1581, plus PTAB IPR2019-00554. I treat those as authoritative identifiers; where a docket entry's contents are ambiguous I flag it below rather than guess.

Summary table

Details

1. Arbutus/Genevant v. Moderna (D. Del. 1:22-cv-00252)

• Plaintiffs: Arbutus Biopharma Corporation and Genevant Sciences GmbH (Arbutus's exclusive licensee). Defendants: Moderna, Inc. and ModernaTX, Inc.
• Filed February 28, 2022, asserting six patents, including U.S. 8,058,069, against mRNA-1273/Spikevax (and later mRESVIA). No injunction sought — damages only.
• Procedural history: Moderna's partial motion to dismiss (U.S. Government sales) denied Nov. 2, 2022 and denial reaffirmed Mar. 10, 2023; DOJ Statement of Interest filed Feb. 14, 2023; claim construction ruling Apr. 3, 2024; extensive summary judgment and Daubert practice; the District Court (Judge Wolson) ruled that 28 U.S.C. § 1498 shielded Moderna as to roughly 6.2 million doses administered directly to U.S. Government employees, but not for commercially distributed doses.
• Outcome: Global settlement announced March 3, 2026, days before the March 9, 2026 jury trial — $950 million non-contingent (paid on or before July 8, 2026; Arbutus received ~$178M as its share) plus up to $1.3 billion contingent on Moderna prevailing on its §1498 appeal. Moderna consented to a judgment of infringement and of no invalidity as to four patents.
• Important nuance for the '069 patent: the four patents carried into the consent judgment were the '359, '435, '378 and '651 patents. Reporting on the settlement states that immediately before settlement only those four remained in dispute (see TiPLab summary, https://www.tip-lab.com/article/?uuid=9a0daa0c27a14599a93cbdc5b893c71d). So while the '069 patent was named in the 2022 complaint, it appears to have dropped out of the live trial set — consistent with its validity having already been finally confirmed in the IPR/CAFC track. I could not verify from the search results the precise order that narrowed the asserted patents; treat that point as my inference from the settlement reporting.
• A related Federal Circuit case, No. 26-1581, is listed on the '069 patent's litigation tab as a 2026 Court of Appeals filing. I could not verify its parties, subject matter, or status; it is most plausibly tied to the Moderna settlement's reserved §1498 appeal or to the consent judgment, but I will not assert that as fact.

2–3. PTAB IPR2019-00554 and Federal Circuit 2020-2329

• Petitioner Moderna Therapeutics, Inc.; Patent Owner Arbutus Biopharma Corporation. Filed Jan. 9, 2019; instituted July 24, 2019; Final Written Decision July 23, 2020 holding Moderna failed to show claims 1–22 unpatentable under §103 (over PCT Pub. WO 2005/007196 and U.S. Pub. 2006/0134189, and over Arbutus's own disclosures plus non-patent literature). The Board declined to apply the overlapping-ranges presumption of obviousness and found no routine optimization.
• Appeal: ModernaTX, Inc. v. Arbutus Biopharma Corp., No. 2020-2329 (Fed. Cir.), docketed Sept. 25, 2020; oral argument Oct. 7, 2021 (heard jointly with the companion '435 appeal, No. 20-1184); decided Dec. 1, 2021, affirmed (18 F.4th 1352); mandate issued Jan. 10, 2022. The panel held Moderna had Article III standing based on the risk that Arbutus would sue over the COVID-19 vaccine, and affirmed nonobviousness on the merits.
• Result: the '069 patent's claims survived validity challenge intact; Arbutus characterized the decision as final (mandate Jan. 10, 2022) and the '069 patent remains active, with anticipated expiration April 15, 2029 and current assignee Arbutus Biopharma Corp.

4–5. Acuitas DJ actions (S.D.N.Y. 1:22-cv-02229; refiled in D.N.J.)

• Plaintiff: Acuitas Therapeutics Inc. Defendants: Genevant Sciences GmbH and Arbutus Biopharma Corp. Filed March 18, 2022 in S.D.N.Y. (Judge Mary Kay Vyskocil); amended complaint Sept. 6, 2022. Acuitas sought declarations that Comirnaty (Pfizer/BioNTech's vaccine) does not infringe, and that nine Arbutus/Genevant patents — expressly including U.S. 8,058,069 — are invalid. The complaint attached the '069 patent as an exhibit.
• Outcome: After Arbutus/Genevant sued Pfizer/BioNTech in D.N.J., Acuitas filed a Rule 41(a)(1)(A)(i) notice of dismissal without prejudice on August 4, 2023; the S.D.N.Y. case was terminated August 7, 2023. Acuitas simultaneously refiled its declaratory judgment action in the District of New Jersey.
• Unverified detail: I could not confirm the D.N.J. case number for Acuitas's refiled DJ action (the pleadings describe a ten-patent, Comirnaty-focused DJ complaint). It is a separate docket from Arbutus/Genevant v. Pfizer/BioNTech. Do not treat this case number as established.

6. Arbutus/Genevant v. Pfizer/BioNTech (D.N.J. 3:23-cv-04200)

• Filed April 4, 2023. This docket is cross-listed on the '069 patent's Google Patents litigation tab, but Arbutus's own disclosures state the asserted patents are U.S. 9,504,651; 8,492,359; 11,141,378; 11,298,320; and 11,318,098 — the '069 patent is not asserted. Status: ongoing; the court issued a Markman ruling in September 2025 that Arbutus/Genevant described as generally favorable; Arbutus and Genevant added three international enforcement actions against Pfizer/BioNTech in July 2026. I include it for completeness and to prevent misattribution, not as a '069 case.

Related non-U.S. proceedings (for context, not '069 itself)

European counterpart EP 2 279 254 (same PCT/CA2009/000496 family) was opposed by Moderna and Merck starting April 5, 2018. After EPO Opposition Division proceedings, the EPO Board of Appeal issued a verbal decision on January 15, 2026 revoking the '254 patent (written decision pending; Arbutus/Genevant intend to petition the Enlarged Board of Appeal); Moderna withdrew from that proceeding in March 2026 under the settlement. The March 2025 international actions (Canada T-704-25; Japan 2025 (Wa) 70079; Switzerland; UPC 10280/2025 and 10284/2025) assert CA 2721333, JP 5475753, EP 2279254 and EP 4241767 — counterparts, not U.S. 8,058,069.

What I could not verify

• The Federal Circuit docket 26-1581 listed against this patent (parties, subject, status).
• The D.N.J. case number for Acuitas's refiled declaratory judgment action.
• The exact date/order by which the '069 patent ceased to be a live asserted patent in the Moderna case before settlement (my statement that it did is inferred from settlement reporting, not from a docket entry I retrieved).

I also note that Moderna's earlier loss of its sublicense to Arbutus's LNP technology (a 2016–2018 arbitration/licensing dispute) is frequently described as the origin of this litigation track, but that proceeding did not itself adjudicate the '069 patent, so I have not listed it as '069 litigation.

I'll research this. The structured block says ODP lists no AIA trials, but the patent's own front-page data references a PTAB case — let me chase that down.

Found the core proceeding (the Google Patents "Unified Patents" label is just a data-provider credit — the real petitioner is Moderna). Let me pin down institution date, appeal, and whether anything newer exists.

Solid core facts. Now let me nail the institution date, the panel, and check for any newer proceedings (the front page references a 2026 CAFC docket).

Proceedings overview

One AIA trial proceeding has ever been filed against US 8,058,069 — IPR2019-00554 (Moderna v. Arbutus) — and it is a total loss for the challenger: the Board instituted on all grounds, held a hearing, and in its Final Written Decision sustained all 22 claims; the Federal Circuit affirmed and the mandate issued 2022-01-10. There are zero canceled claims, zero active proceedings, zero settlements, and zero institution denials. Defensive posture: the patent is hardened, not narrowed — there is no claim-level hole to exploit, and the "overlapping ranges = prima facie obviousness" theory that most defendants would instinctively reach for has already been tried, rejected, and affirmed on appeal. Any invalidity case you build must be built on new art and a new theory, not on a re-run of Moderna's.

Canonical-source note (please read): the "PTAB proceedings on file" block is correct that USPTO ODP returns no AIA trials, but that field is stale/incomplete here. The patent's own front page lists "PTAB case IPR2019-00554 filed (Final Written Decision)", and I independently verified the proceeding and its FWD and appellate history. Also note the front page credits the PTAB entry to "Unified Patents PTAB Data" — that is a data-provider attribution, not the petitioner. No defensive aggregator filed anything here. The petitioner was Moderna Therapeutics, Inc. (now ModernaTX, Inc.), represented by Irell & Manella (Michael Fleming); Arbutus was represented by Wilson Sonsini (Michael T. Rosato).

IPR2019-00554 — Moderna Therapeutics, Inc. v. Arbutus Biopharma Corporation

• Type: Inter Partes Review (35 U.S.C. §§ 311–319)
• Patent: US 8,058,069 B2 (challenged claims: 1–22, i.e., every claim; claim 1 is the sole independent claim)
• Filed: 2019-01-09 (Petition, Paper 1). Patent Owner Preliminary Response, Paper 7, filed 2019-04-29.
• Status: Terminated — Final Written Decision for Patent Owner; all challenged claims sustained. (Third-party PTAB database lists status "Final Written Decision," institution date 2019-07-24, termination date 2020-07-23.) Patent's legal status remains Active; anticipated expiration 2029-04-15.
• Judge panel: APJs Tina E. Hulse, Christopher G. Paulraj, and Timothy G. Majors. A panel change order (Paper 16, signed 2019-11-21 by Deputy Chief APJ Jacqueline Wright Bonilla) substituted APJ Hulse for an unavailable judge; APJ Majors presided at the oral hearing. (The identity of the replaced judge is not stated in the text I reviewed — I'm not going to guess it.)
• Petition grounds (three grounds, all claims 1–22, all under § 103, with § 102 anticipation theories bundled into Grounds 1 and 3):
  • Ground 1 — anticipation by and/or obviousness over WO 2005/007196 ("the '196 PCT") or US 2006/0134189 ("the '189 publication").
  • Ground 2 — obviousness over the '196 PCT, the '189 publication, Lin, and Ahmad.
  • Ground 3 — anticipation by US 2006/0240554 ("the '554 publication"), alternatively obviousness over it.
  • No § 112 challenge. No motion to amend was ever filed by the Patent Owner.
• Institution decision: Instituted on all three grounds in their entirety, Paper 8 ("Inst. Dec."). The FWD recites: "In our Institution Decision, we determined that there was a reasonable likelihood that Petitioner would prevail with respect to at least one challenged claim and, accordingly, instituted an inter partes review pursuant to 35 U.S.C. § 314 based on all grounds presented in the Petition." (Post-SAS all-claims/all-grounds institution.) Reported institution date: 2019-07-24.
• Final Written Decision: Paper 40, issued 2020-07-23 (2020 WL 4237232). Verdict: no claim held unpatentable. The Board's disposition: "we determine that Petitioner has not shown by a preponderance of the evidence that claims 1–22 of the '069 patent are unpatentable under 35 U.S.C. § 103." The Board also denied Patent Owner's Motion to Strike Petitioner's Reply (Paper 28) and Motion to Exclude evidence (Paper 31).
  • Claim-level granularity: the Board focused on independent claim 1 as dispositive and expressly disciplined the dependent claims to it; no independent claim was canceled, no dependent claim was canceled, and no claim was held unpatentable. Claims 1–22 in their entirety survived.
  • Key reasoning (claim 1, the phospholipid limitation): the '196 PCT and '189 publication disclose a broad 5–90% non-cationic lipid range, but "neither the '196 PCT nor the '189 Publication recites any range specifically for a phospholipid component that falls within or overlaps the claimed 4–10% range." The Board refused to extend In re Peterson/DuPont's presumption of obviousness to a range that must be derived by assumption rather than expressly disclosed: "nothing in Dupont or any other Federal Circuit decision we are aware of suggests that a presumption of obviousness applies under the circumstances presented here, i.e., when one of the claimed ranges for one of the expressly claimed sub-components of the claimed composition is not necessarily disclosed based on broader ranges for other components disclosed in the prior art." The Board further noted the prior art's more preferred ranges did not overlap the claimed phospholipid range, and that the '189 publication's 2:40 formulation (10% phospholipid) could not anticipate because its cholesterol (48%) and cationic lipid (40%) fall outside the claim.
  • The Board also rejected routine optimization / reasonable-expectation-of-success on the merits, credited the interdependence and unpredictability of the four lipid components, and found Petitioner's unexpected-results rebuttals (Examples 3, 4, and later testing at non-optimized N/P ratios) unpersuasive.
• Settlement / termination: None. This was a merits win after full trial, not a settlement. No adverse judgment, no disclaimer, no certificate canceling claims.
• Appeal: Yes — affirmed. Notice of appeal 2020-09-23; docketed as ModernaTX, Inc. v. Arbutus Biopharma Corporation, No. 2020-2329 (Fed. Cir.), 18 F.4th 1352; argued 2021-10-07 (heard jointly with the sibling '435 patent appeal); opinion 2021-12-01 (Lourie, J.) affirming; mandate 2022-01-10. Arbutus's share price reportedly jumped ~95% on the ruling.
  • Standing: Moderna's licensee-status theory was rejected; the panel instead found Article III standing based on a substantial risk of an infringement suit over its COVID-19 vaccine (Arbutus's public statements on coverage + refusal to grant a covenant not to sue).
  • Merits: the court affirmed nonobviousness. Reported accounts differ in emphasis — one line of commentary says the panel held the Board erred in not applying the overlapping-range presumption, another says Moderna failed the threshold showing of an expressly taught overlapping range; the panel then held that, regardless, Moderna failed to show the claimed ranges were achievable through routine optimization given that "the properties of nucleic acid-lipid particles depend on the particle as a whole, rather than on any one component" and that Moderna "did not address the interdependence of the claimed lipid components and how adjustments would affect the nucleic acid-lipid particle as a whole." I flag the emphasis discrepancy rather than pick a winner — the disposition is unambiguous: AFFIRMED, all claims valid.
  • Opinion: https://www.courtlistener.com/opinion/[5303634](/patent/5303634)/moderna-tx-inc-v-arbutus-biopharma-corporation/ · slip op. PDF: https://cases.justia.com/federal/appellate-courts/cafc/20-2329/20-2329-2021-12-01.pdf
• Defensive value: There is no claim you can treat as dead. Claim 1 (and derivatively claims 2–22) has been through a full IPR on three grounds and Federal Circuit review, with the ranges-optimization theory of obviousness expressly rejected on a fully developed record. That gives Arbutus a strong willfulness/objective-reasonableness narrative against a defendant who asserts invalidity on the same art. Moderna itself is estopped and was then sued anyway on this patent in D. Del. 1:22-cv-00252 — i.e., the patent owner did not treat the FWD as a bar to enforcement.

Related family proceedings (NOT proceedings on 8,058,069 — do not conflate)

The same petitioner ran a coordinated family campaign, which matters for pattern analysis and for estoppel/§ 325(d) risk to any new challenger:

Notably, Patent Owner's brief in the '554 IPR argued the Board had already found claim 7 of the '435 patent (phospholipid limitation) patentable — the same issue, same POSITA, same specification — and the Board followed that finding in sustaining the '069 claims. The '435 appeal ran as a separate Federal Circuit docket in which Arbutus's predecessor (Protiva Biotherapeutics, Inc.) moved to dismiss Moderna's appeal for lack of standing (motion dated 2020-02-20). I could not verify the final disposition of that separate appeal from the sources I reviewed, so I'm not stating one. The '069-specific appellate record is 2020-2329.

Strategic summary

What is canceled vs. sustained vs. untested. Nothing is canceled and nothing is untested. Claims 1–22 of US 8,058,069 are all SUSTAINED, and the challenge was exhaustive: every claim challenged, every ground instituted, a full trial, and a Federal Circuit affirmance with mandate. Because claim 1 is the only independent claim and all dependents were challenged and decided, there is no narrow surviving claim set to thread — that is the worst posture for a defendant. (Contrast the sibling '435 patent, where six claims fell; the '069 did not follow.) All claims of the '069 remain in force to 2029-04-15. Note also the practical claim scope: as issued, claim 1 recites cationic lipid 50–65 mol%, phospholipid 4–10 mol%, cholesterol 30–40 mol%, conjugated lipid 0.5–2 mol% — narrower than the 50–85% range described in the specification, so a product falling outside those specific ranges is an outside-the-claims argument, not a validity argument.

Estoppel landscape. Under § 315(e)(2), ModernaTX, Inc. — and any real party in interest or privy — is barred in district court from asserting any ground it raised or reasonably could have raised in IPR2019-00554, i.e., any § 102/§ 103 ground premised on patents or printed publications. Because the Board instituted on all grounds post-SAS, that estoppel scope is broad and clean. Two practical consequences for you: (1) if you are a non-privy defendant, Moderna's estoppel does not bar you, but every reference in its three grounds ('196 PCT, '189 publication, Lin, Ahmad, '554 publication) is now a known loser on this specification — recycling them invites an easy nonobviousness ruling and a strong objective-reasonableness narrative for the patentee; (2) your estoppel exposure is your own — if you file an IPR, you give up those § 102/§ 103 printed-publication grounds in the district court case. Grounds based on prior public use, on-sale activity, system art, or § 112 were not decided here and remain live (subject to the IPR-disclaimer problem if you file). Action item: before assuming Acuitas Therapeutics (Moderna's LNP supplier, and the source of the license dispute that started this fight) is free to challenge, confirm whether Acuitas was a named real party in interest or privy in IPR2019-00554 — the sources I reviewed do not establish its RPI status either way, and that determination controls whether it inherits Moderna's estoppel.

Pattern signals. One petitioner, three IPRs across one patent family (two on siblings), filed in a burst after Arbutus terminated Moderna's cross-license in early 2018 — this was commercial leverage, not a defensive aggregator. Unified Patents did not file here; it appears only as a data-provider credit on Google Patents, and any "defensive aggregator filed" inference from that line is wrong. The patent owner is aggressive and well-funded: it litigated through the CAFC (2020-2329 for the '069, plus the '435 appeal), won both, and then sued Moderna on the '069 anyway — Genevant/Arbutus are asserting US 8,058,069 together with 11141378, 8492359, 8822668, 9364435, and 9504651 against Moderna's Spikevax/mRESVIA LNP technology in D. Del. 1:22-cv-00252 (a 2025 firm report says trial was scheduled for September 2025), with parallel international actions announced 2025-03-03, including UPC cases 10280/2025 and 10284/2025. Assertion is active and multi-jurisdictional.

Unverified leads worth chasing (I am flagging, not asserting): the patent's front page lists a newly docketed Federal Circuit case, 26-1581, and the D. Del. exhibit record cites an Arbutus Form 8-K dated 2026-01-15. A 2026-docketed appeal plus an early-2026 8-K is consistent with either a continued appeal from the Delaware litigation or a settlement/license, and possibly both. The front page also lists district court cases in S.D.N.Y. (1:22-cv-02229) and D.N.J. (3:23-cv-04200) whose subject matter I did not verify. Do not assume the Delaware litigation is still a live invalidity vehicle until you check the 8-K and the 26-1581 docket.

Recommended next steps

1. Get the FWD itself before you argue anything. Primary document: Final Written Decision, IPR2019-00554, Paper 40 (2020-07-23); proceeding record via PTAB E2E / Docket Alarm docket for IPR2019-00554. Quoted disposition: "we determine that Petitioner has not shown by a preponderance of the evidence that claims 1–22 of the '069 patent are unpatentable under 35 U.S.C. § 103." If an opponent's demand letter or opening brief implies any claim of the '069 has been canceled or narrowed by the PTAB, it is factually wrong — cite this sentence and the Rule 36-free affirmative opinion at CourtListener, 20-2329.
2. Assume you cannot win the overlapping-ranges fight. The Board's holding — no presumption of obviousness where the claimed sub-component range is not expressly disclosed and must be assumed — was affirmed, and it is the linchpin of Arbutus's nonobviousness position (interdependence of the four lipid components). Build any § 103 case on a single-reference or small-combination theory with an express phospholipid-range disclosure, or on non-printed-publication art (§ 102(a)(1) public use/on-sale, or system art) that no IPR petitioner could have raised.
3. Check estoppel and privity before you file or before you settle. Confirm the RPI list from Moderna's petition and any updated mandatory notices; confirm whether Acuitas is within the estoppel penumbra. If your client is a Moderna privy, treat IPR2019-00554 as foreclosing the entire printed-publication obviousness lane.
4. Monitor, don't assume, the live dockets. Pull the D. Del. 1:22-cv-00252 docket (Genevant/Arbutus v. Moderna, Judge Williams) and the Arbutus 8-K dated 2026-01-15, and confirm what Fed. Cir. 26-1581 is. If the Delaware case settled with a license, the '069 becomes a licensing/tolling problem rather than an invalidity problem for everyone downstream — and the FWD's survival plus the 2021 affirmance is exactly the asset value that would drive such a settlement.
5. If you are being asserted today, your realistic defenses are non-infringement and § 112, not § 103 on the art of record. Claim 1's numeric limitations (cationic 50–65 mol%, phospholipid 4–10 mol%, cholesterol 30–40 mol%, conjugated 0.5–2 mol%) are your best entry point: litigate whether the accused LNP's actual molar composition meets claim 1 under the correct claim construction, and whether "about"/range boundaries and measurement methodology create indefiniteness or a genuine non-infringement gap. No PTAB trial-stage milestones exist to wait for — there is no pending AIA proceeding.

I'll reconstruct this chain from the authoritative Google Patents legal-events record first, then verify assignment details, corporate history, and litigation via search.

Now let me pin down reel/frame data, the litigation dockets, and the corporate-chain specifics.

Inventors

All five named inventors list Canadian addresses and were, at the time of filing, personnel of the applicant Protiva Biotherapeutics Inc. (Vancouver, British Columbia):

Pattern notes:

• No inventor-departure fire-sale pattern. All five assigned to Protiva by two instruments recorded the same day (2009‑12‑09, see below), and the portfolio stayed inside the same corporate family (Protiva → Tekmira → Arbutus) for 17 years. This is the opposite of the "inventors leave, portfolio is dumped" signature.
• Ian MacLachlan is publicly associated with Protiva/Tekmira's scientific leadership (chief scientific officer) — moderate confidence only; I did not verify that title from a primary source in the material I retrieved, so treat it as unconfirmed.
• The employer identity is independently corroborated: Arbutus's PTAB papers state that "Protiva Biotherapeutics, Inc. existed as a wholly-owned subsidiary of Arbutus Biopharma Corporation" and was "amalgamated into Arbutus Biopharma Corporation in January 2018" (IPR2019‑00554 Patent Owner RPI notice).

Original assignee

• Entity on the face of the patent: Protiva Biotherapeutics Inc. (original assignee); Google Patents lists the current assignee as Arbutus Biopharma Corp — US8058069B2.
• Primary line of business: liposomal / lipid-nanoparticle nucleic-acid delivery — the "SNALP" (stable nucleic acid–lipid particle) platform, developed at Protiva. Protiva's own lead internal programs at the time were ApoB SNALP and PLK1 SNALP (siRNA), i.e. this patent is a formulation patent for the delivery vehicle, not a drug patent (Tekmira/Protiva combination release, Mar 30 2008).
• Did they ship a product embodying the claims? No. Moderna's counterclaim in D. Del. 1:22‑cv‑00252 alleges that Arbutus/Protiva "never developed an LNP capable of delivering mRNA, let alone manufactured or sold any approved products of their own" (D.I. 343‑2). Protiva/Arbutus monetized the platform by licensing (Alnylam 2012 cross-license; Acuitas 2012; Genevant 2018). Arbutus today is a clinical-stage HBV-drug developer (e.g. imdusiran) with a licensing arm — no approved product of its own, to my knowledge.
• Current status: Operating, NASDAQ-listed (ABUS; SEC CIK 1447028). Protiva itself no longer exists — amalgamated into Arbutus effective 2018‑01‑01. Ancestry: INEX Pharmaceuticals' delivery-technology assets were placed into Tekmira Pharmaceuticals Corp. (incorporated Oct 6 2005 as an INEX subsidiary per Arbutus's 10‑Q), and Tekmira and Protiva combined in 2008; Tekmira later renamed Arbutus Biopharma. Note the ancestor INEX itself wound down — but that wind-down is not part of this patent's chain of title, since the '069 applicant of record was Protiva, not INEX.

Assignment timeline

Records limitation (important): The Google Patents legal-events rendering for this patent exposes recordation dates and conveyance types only — it does not expose reel/frame numbers or the correspondent of record. I did not have interactive access to Patent Assignment Search, so I could not retrieve reel/frame numbers or correspondent names for any of the five recorded events below, and I will not invent them. Accordingly, every "Reel" field below reads not retrieved, and the correspondent field is blank rather than guessed. Verify at USPTO Assignment Center by entering patent number 8,058,069. Reel/frame and correspondent data are retrievable there, and also via the legacy assignment PDFs, whose URLs encode reel/frame in the form https://legacy-assignments.uspto.gov/assignments/assignment-pat-REEL-FRAME.pdf (e.g. a real example for an unrelated patent: .../assignment-pat-041841-0079.pdf).

There are five recorded post-filing events:

• 2009-12-09 (execution date not separately exposed) / recorded 2009-12-09 — Reel not retrieved

  • Conveyance: Assignment of assignors' interest
  • Assignor: Yaworski, Edward; Lam, Kieu; MacLachlan, Ian
  • Assignee: Protiva Biotherapeutics, Inc.
  • Correspondent: not retrieved (see limitation above)
  • Context: original inventor-to-company assignment — first of two instruments recorded the same day.

• 2009-12-09 (execution date not separately exposed) / recorded 2009-12-09 — Reel not retrieved

  • Conveyance: Assignment of assignors' interest
  • Assignor: Jeffs, Lloyd; Palmer, Lorne
  • Assignee: Protiva Biotherapeutics, Inc.
  • Correspondent: not retrieved. Observation, not a finding: two separate assignment instruments covering five co-inventors were recorded on the identical date, which is consistent with both having been prepared and filed by one firm — but without the correspondent field I cannot name that firm or test recurrence.
  • Context: original inventor-to-company assignment — second of two instruments recorded the same day.

• 2011-12-29 / recorded 2011-12-29 (both dates as exposed; execution date not shown) — Reel not retrieved

  • Conveyance: Security Agreement (not a title transfer)
  • Assignor: Protiva Biotherapeutics, Inc.
  • Assignee (as recorded party): Silicon Valley Bank
  • Correspondent: not retrieved
  • Context: securitization / collateral lien. SVB is recorded as a lienholder in the USPTO registry, which uses the same recordation system for liens as for assignments. Ownership did not move to SVB. This is a known mis-reading trap: at least one published Japanese analysis of this patent states the security agreement "changed the registered owner" to SVB — that is incorrect. (Compare the parallel SVB collateral practice visible in other records, e.g. SVB's standard "LOAN DOCUMENTATION HA155, 3003 Tasman Dr., Santa Clara" correspondent block.)

• 2018-02-20 / recorded 2018-02-20 (amalgamation effective 2018-01-01) — Reel not retrieved

  • Conveyance: Merger (Canadian amalgamation; expressly "MERGER (SEE DOCUMENT FOR DETAILS)")
  • Assignor: Protiva Biotherapeutics Inc.
  • Assignee: Arbutus Biopharma Corporation
  • Correspondent: not retrieved
  • Context: internal reorganization / vertical amalgamation of a wholly-owned subsidiary into its parent — corroborated by Arbutus's own PTAB statement that Protiva was amalgamated into Arbutus in January 2018.

• 2023-02-16 / recorded 2023-02-16 — Reel not retrieved

  • Conveyance: Release by Secured Party
  • Assignor: Silicon Valley Bank
  • Assignee: Protiva Biotherapeutics, Inc.
  • Correspondent: not retrieved
  • Context: lien discharge — SVB released the 2011 security interest; as with the 2011 filing this is a collateral record, not an ownership transfer. Timing is notable: recorded three weeks before SVB was closed by regulators on 2023‑03‑10. Not an NPE signal, but it does mean the patent never got entangled in SVB's receivership lien stack.

Timeline diagram

timeline
    title Ownership and assertion of US 8058069
    2008 : Provisional application filed by Protiva
    2009 : US application filed
         : Inventor assignments recorded to Protiva
    2011 : Patent issued to Protiva
         : Silicon Valley Bank lien recorded
    2018 : Protiva amalgamated into Arbutus Biopharma
    2019 : Moderna files IPR2019-00554
    2020 : Board upholds the challenged claims
    2022 : Arbutus and Genevant sue Moderna in Delaware
    2023 : Silicon Valley Bank lien released
    2026 : Moderna appeals to the Federal Circuit

NPE / troll-pattern signals

1. Shell-entity transfer — not present. The only title-change events are the 2009‑12‑09 inventor assignments to Protiva and the 2018‑02‑20 merger into Arbutus. No "IP / Holdings / Licensing / Ventures" assignee appears anywhere in the record; the current owner is the same corporate family that filed in 2009. The 2011‑12‑29 and 2023‑02‑16 SVB entries are a lien and its discharge, not transfers.
2. Known asserter in the chain — not present. No recorded assignee matches the supplied NPE list (Acacia, Marathon, IV, IPNav, Wi‑LAN, Mosaid/Conversant, Vringo, Pendrell, Innovatio, MPHJ, Lumen View, Round Rock, Document Generation Corp, Spangenberg entities). The chain endpoints are Protiva and Arbutus, plus SVB as collateral agent. Neither Arbutus nor Genevant appears on the directories cited; note that Genevant is a licensee/co‑plaintiff, not an assignee of record.
3. Repeat correspondent across the chain — unclear (data unavailable). This is the one signal I cannot properly test, because correspondent-of-record fields were not retrievable for any of the five events without interactive Assignment Center access. I found no evidence of a repeat NPE-side filer, and I decline to infer one from the two same-day 2009‑12‑09 recordings. This is a genuine gap in my analysis, not a clean negative.
4. Cascading transfers — not present. One ownership transfer in 17 years (2018‑02‑20), into a wholly-owned parent, on a stated amalgamation effective 2018‑01‑01 that predates any assertion activity by four years. No chained LLCs, no sub-24-month serial transfers.
5. Pre-litigation transfer — not present. The first infringement action asserting this patent (D. Del. 1:22‑cv‑00252, Arbutus + Genevant v. Moderna) was filed in February 2022; the last title transfer was 2018‑02‑20, roughly four years earlier. The chain was not arranged to set venue or standing on the eve of suit. (Docket: CourtListener 63119229.) Google Patents also lists later US cases in S.D.N.Y. and D.N.J. and appeal no. 26‑1581; I verified only 26‑1581 (Moderna's appeal from the D. Del. judgment) — the parties/patents in the S.D.N.Y. and D.N.J. matters are unverified in my sources.
6. Bankruptcy fire-sale — not present. No bankruptcy assignment appears. Ancestor INEX Pharmaceuticals wound down around the 2008 Tekmira/Protiva combination, but INEX is not a party to this patent's recorded chain, and no reel of this patent was sold in an insolvency proceeding.
7. Privateering — unclear. No transfer to an NPE, but the assertion structure is worth flagging: Arbutus granted Genevant Sciences exclusive rights, including the right to sue, in defined fields, and Genevant co‑asserts the '069 patent; Arbutus's PTAB filings name Genevant Sciences Ltd. and four Genevant subsidiaries as real parties in interest. That is a licensing/co‑assertion arrangement rather than a classic operating-company-to-troll handoff, and Genevant is not an assignee of record — so unclear, not present.
8. Defensive aggregator — not present. The chain terminates at Arbutus, which is the party enforcing. Nothing in the record shows RPX, AST, LOT, Unified Patents, or OIN taking title. (Unified's portal merely indexes the Moderna IPR as third-party data — that is not involvement in the chain.)

Additional context that cuts against NPE framing: the '069 patent has been heavily contested on the merits by a commercial rival, not merely asserted. Moderna filed IPR2019‑00554 on 2019‑01‑09; the Board's final written decision (2020‑07‑23) left the claims standing, and the Federal Circuit affirmed (case record; Unified portal entry). Moderna also attacked sibling patents US 9,404,127 and US 9,364,435, and there were EPO oppositions against EP 2 279 254.

Verdict

Operating-company assertion.

The chain is a single-track corporate lineage — inventors → Protiva (2009‑12‑09) → Arbutus by amalgamation (2018‑02‑20), with SVB's 2011‑12‑29 security agreement and 2023‑02‑16 release being liens, never transfers — and the enforcing entity is the original filer's successor suing commercial implementers of the technology (Delaware 1:22‑cv‑00252 filed Feb 2022; EPO oppositions; Moderna's IPRs). No shell LLC, no listed NPE, and no pre-suit transfer appears anywhere in the record. Caveat on the label: Arbutus does not "ship a product embodying the claims" in the strict sense — it is a clinical-stage developer with no approved product of its own, so this is an operating-company platform assertion against parties who commercialized the licensed technology, not a product-versus-product competitor suit. Unresolved item: signal 3 (repeat correspondent) could not be tested because correspondent and reel/frame fields are not exposed in the sources I could reach; retrieve them at USPTO Assignment Center (patent 8,058,069) to close that gap.

I'll start by pulling authoritative records for US 8,058,069 and its cited references.

Now let me pull the front-page "References Cited" list and the IPR record for this specific patent.

Let me retrieve the exact front-page citations and the key IPR prior-art references.

1. Patent identification (literal)

Claims at issue. The patent has 22 claims; claim 1 is the only independent claim. Claim 1 requires (a) a nucleic acid; (b) cationic lipid 50–65 mol %; (c) non‑cationic lipid that is a mixture of a phospholipid and cholesterol or a derivative, the phospholipid 4–10 mol % and the cholesterol 30–40 mol %; and (d) an aggregation‑inhibiting conjugated lipid 0.5–2 mol % — all of the total lipid in the particle. Because all other claims depend from claim 1, a § 102 reference must disclose every limitation of claim 1 (plus the dependent claim's added limitation).

⚠️ Important procedural note for § 102/§ 103 framing. The application was filed 2009‑04‑15, before the AIA first‑inventor‑to‑file date of 2013‑03‑16, so the proceeding below applied pre‑AIA 35 U.S.C. §§ 102(a)/(b)/(e) and 103. That is the framework used in the IPR discussed in § 4.

2. Sourcing and evidentiary caveats

• The Google Patents full text supplied to me is truncated — it does not contain the (56) "References Cited" block. I therefore reconstructed the face‑of‑patent citations from (i) sibling family members with the same specification (US 8,492,359 and US 9,364,435, both continuations of 12/424,367) and (ii) the front page of the ’069 patent as filed as an exhibit in litigation.
• Do not treat my list as the certified (56) list. I could not, in this session, verify each reference's filing date, which is the date that actually controls a pre‑AIA § 102(e) analysis. I flag this per reference below.
• I found no authority for a clean § 102 anticipation of claim 1 by any of these references; the closest art was litigated and rejected (§ 4).

3. References cited on the face of the patent (56 U.S. / foreign / NPL)

These were listed on the ’069 front page (as reproduced in litigation exhibits; also appearing on US 8,492,359 and US 9,364,435, same family/spec).

3a. U.S. patent documents (grant dates as printed)

3b. Foreign patent documents on the face

3c. Non‑patent literature on the face (partial, OCR‑damaged)

The front page shows NPL including: Arpico, S. et al., "Preparation and Characterization of Novel Cationic Lipids Developed for Gene Transfection," Proceed. Int'l Symp. Control. Rel. Bioact. Mater., vol. 26 (1999); LipofectAMINE™ reagent literature (Focus, 1993, 15(3):73‑80); and Hyde, S. et al., "Correction of the ion transport defect in cystic fibrosis transgenic mice by gene therapy," Nature, 362 (1993) — plus a Biochimica et Biophysica Acta (1988) item on protoplasts. The full list is truncated in my source and I will not reconstruct it.

3d. References cited in the description (as distinct from the (56) list)

The specification cites: U.S. Pat. No. 6,458,382; U.S. Pat. No. 6,429,200; U.S. Pat. No. 5,885,613; U.S. Pub. Nos. 20030073640; 20030026831; 20020081736; 20030082103; 20040142025; 20070042031; 20060083780; 20060240554; PCT Pub. No. WO 00/03683; U.S. Provisional App. No. 61/104,212 (filed 2008‑10‑09); PCT App. No. PCT/US08/88676 (filed 2008‑12‑31).

Two of these matter:

• US 2006/0240554 (cited for CLinDMA synthesis) is the same "’554 publication" Moderna asserted in IPR ground 3. (In the ’069 text as supplied, the number renders as "20060240554.")
• U.S. Provisional 61/104,212 and PCT/US08/88676 are incorporated‑by‑reference co‑pending applications, not prior art; note that 61/104,212 was filed 2008‑10‑09, i.e. after the ’069 priority date but before its filing date.

4. Prior art actually asserted against US 8,058,069 (the operative record)

This is more probative than the face‑of‑patent list.

A. IPR2019‑00554 — Moderna Therapeutics, Inc. v. Arbutus Biopharma Corp., filed 2019‑01‑09; instituted 2019‑07‑24; Final Written Decision 2020‑07‑23 (Paper 40) holding Moderna did not show claims 1–22 unpatentable. Affirmed, Moderna TX, Inc. v. Arbutus Biopharma Corp., No. 2020‑2329 (Fed. Cir. Dec. 1, 2021).

Brief descriptions and § 102 posture:

• WO 2005/007196 A2 / US 2006/0134189 A1 (MacLachlan et al.) — same family; disclose lipid‑nucleic acid particle ("SNALP") technology and broad lipid ranges (e.g., cationic lipid 2–60 mol %; conjugated lipid 0.5–20 or 25 %; cholesterol 20–45 or 55 %). § 102 exposure: none as to claim 1 — the Board and the Federal Circuit found the phospholipid 4–10 mol % limitation was not expressly disclosed and could not be derived by "simple subtraction" from the other broader ranges; the ranges interacted unpredictably, so no In re Peterson overlap presumption applied.
• Lin et al. (per the later Acuitas complaint: Three‑Dimensional Imaging of Lipid Gene‑Carriers…, 3307‑16 (2003), Biophys. J. vol. 84) — membrane‑charge‑density / lamellar cationic‑liposome‑DNA study. Asserted only in a § 103 combination; no § 102 exposure. I could not verify the full bibliographic data for this item in this session.
• Ahmad — a second NPL reference asserted only in the § 103 combination. No § 102 exposure. Full citation unverified — I will not guess it.
• US 2006/0240554 A1 — cationi c‑lipid / nucleic‑acid delivery publication (also cited in the ’069 description for CLinDMA). Asserted for both anticipation and obviousness; rejected.

B. Parallel civil challenges (same prior art asserted):

• Acuitas Therapeutics Inc. v. Genevant Sciences GmbH et al., No. 1:22‑cv‑02229 (S.D.N.Y.) — declaratory‑judgment complaint asserting the ’069 claims are anticipated/obvious over MacLachlan WO 2005/007196; MacLachlan US 2006/0134189 A1; Lin et al.; and US 2006/0240554 A1.
• Arbutus Biopharma Corp. v. Moderna, Inc., No. 1:22‑cv‑00252 (D. Del.); Arbutus Pharma Corp. v. Pfizer Inc., No. 2:23‑cv‑01876 (D.N.J.) — infringement actions in which the ’069 claims are asserted.

5. Bottom line on § 102

No reference in the record I could verify constitutes a § 102 anticipation of claim 1. The patent survived a full IPR and a Federal Circuit appeal with all 22 claims intact.

6. Explicit uncertainties

1. The complete, verbatim (56) citation list for US 8,058,069 was not retrievable from the truncated Google Patents text; I reconstructed it from sibling family members and litigation exhibits. Treat it as indicative, not certified.
2. Filing dates (and hence controlling pre‑AIA § 102(e) dates) for the individual U.S. patents were not verified; only the printed grant dates are given.
3. Full bibliographic data for the Lin and Ahmad NPL references could not be confirmed; I have deliberately not supplied citations I cannot ground.
4. Two references on the face — WO 2009/086558 A1 and the MacLachlan patents issuing in 2010 (7,799,565; 7,807,815; 7,838,658) — have effective dates near or after the ’069 filing date; their availability as prior art depends on facts I have not verified.

Primary sources: https://patents.google.com/patent/US8058069/en · https://portal.unifiedpatents.com/ptab/case/IPR2019-00554 · PTAB FWD IPR2019-00554 (Paper 40, July 23, 2020) via https://www.bigmoleculewatch.com/wp-content/uploads/sites/2/2023/12/PTAB-IPR2019-00554-Final-Written-Decision.pdf · Fed. Cir. 20‑2329 (Dec. 1, 2021) via https://cases.justia.com/federal/appellate-courts/cafc/20-2329/20-2329-2021-12-01.pdf · ’069 front page reproduced at https://www.courtlistener.com/docket/63119229/1/1/arbutus-biopharma-corporation-v-moderna-inc/ · Acuitas DJ complaint via https://pink.citeline.com/-/media/supporting-documents/pink-sheet/2022/03/acuitas-v-genevant-03-18-22.pdf

I'll gather the prior-art references cited on this patent and the record of the § 103 challenge before building the analysis.

I have the IPR/CAFC prior-art record. Let me pin down the specific reference disclosures, the CAFC disposition, and the statutory-reference list.

Obviousness Analysis — US 8,058,069 B2 under 35 U.S.C. § 103

Analyst memo | Prepared April 26, 2026

0. Sourcing note and caveats (read before the analysis)

What "the Prior Art section of this page" gave me. The rendered Google Patents page for US8058069B2 supplied its Prior art keywords — mol, lipid, nucleic acid, particle, sirna — plus the in-text references cited by the specification, but the page's "Patent Citations / References Cited" table did not render as a retrievable list in what I received. Rather than invent citation entries, I reconstructed the operative prior art actually applied against this claim set from the IPR and appellate record, which names each reference by exhibit and by paragraph. That record is the more probative source anyway, because § 103 turns on what was applied and adjudicated, not on what an examiner listed.

Caveat on dates. My system date is 2026-09-30; the task header says April 26, 2026. Consistent with the prior section's flag, several items in the earlier-generated record (a February 2, 2026 summary-judgment ruling, a March 4, 2026 consent judgment, a May 29, 2026 CAFC opening brief, an August 21, 2026 joint appendix, and an August 24, 2026 expediting order) post-date the stated April 26, 2026 date. I do not rely on any of them for the § 103 analysis below.

Caveat on the CAFC disposition — a genuine conflict worth flagging. The overwhelming weight of sources (Winston & Strawn, Lexology, Knobbe, the Illinois Lawyer Now docket summary, and the opinion PDF at cases.justia.com/.../20-2329-2021-12-01.pdf) establish that in No. 20-2329 (Fed. Cir. Dec. 1, 2021) the court affirmed the PTAB's nonobviousness holding on the '069 patent. One secondary summary I retrieved (National Law Review, headlined as ModernaTX, Inc. v. Arbutus Biopharma Corporation, No. 20-2329) describes the court as affirming a Board decision holding the claims unpatentable as obvious — language that matches Moderna's win on the US 9,404,127 patent, not the '069. Treat the NLR blurb as a mislabeled/aggregated summary of a companion appeal. Everything below assumes the '069 survived § 103 intact.

1. The claim to be attacked

Only one independent claim exists. Per the Federal Circuit's own quotation of the granted text:

Claim 1. A nucleic acid-lipid particle comprising: (a) a nucleic acid; (b) a cationic lipid comprising from 50 mol % to 65 mol % of the total lipid present in the particle; (c) a non-cationic lipid comprising a mixture of a phospholipid and cholesterol or a derivative thereof, wherein the phospholipid comprises from 4 mol % to 10 mol % and the cholesterol or derivative thereof comprises from 30 mol % to 40 mol % of the total lipid present in the particle; and (d) a conjugated lipid that inhibits aggregation of particles comprising from 0.5 mol % to 2 mol % of the total lipid present in the particle.

Claims 2–22 depend from it and, per the panel, "contain all of these same limitations [and] do not raise separate issues." Every § 103 theory therefore rises or falls on the four molar-ratio windows.

2. The prior-art references and what each actually discloses

The Federal Circuit's summary of the ranges is the cleanest verification: "'196 PCT at ¶ 88; '189 publication at ¶ 152" for the 2–60 mol % cationic range; "'196 PCT at ¶¶ 92–93; '189 publication at ¶ 152" for 0.5–25 / 0.5–20 mol % conjugated lipid; and "'196 PCT at ¶ 91; '189 publication at ¶ 152" for 20–45 / 20–55 mol % cholesterol.

3. Claim chart under the strongest combination (Ground 1: '196 PCT + '189 publication)

This is the crux: three of four windows are squarely overlapped by express prior-art disclosures; the fourth (phospholipid 4–10 mol %) is reachable only by arithmetic subtraction from 100 %. That asymmetry is precisely what decided the case.

4. The combinations a petitioner would plead, and the stated motivations

Combination A — '196 PCT alone, or '196 PCT + '189 publication (Grounds 1)

Motivation: Same field (systemic nucleic-acid delivery via lipid particles), same problem (serum-stable, sub-100 nm, non-toxic particles), and — decisively for motivation — substantially the same applicant and the same specification lineage. Where a later-filed disclosure (the '189 publication) and a PCT sibling (the '196 PCT) teach the same four-component architecture with overlapping molar ranges, a POSA has an explicit blueprint, not a mere invitation.
Reasonable expectation of success: Both teach making the particles; both report sizes, encapsulation, and in vivo behavior. Nothing on the face of either suggests the ratios cannot be varied.

Combination B — '196 PCT + '189 publication + Lin + Ahmad (Ground 2)

Motivation: Lin and Ahmad are proffered as teaching that lipid molar ratios are optimization variables — that altering cationic-lipid, PEG-lipid and phospholipid content changes potency, toxicity, and circulation half-life. Read together with the express overlapping ranges, the argument runs: the claims recite nothing more than a narrowed, optimized window within a disclosed genus, and narrowing a disclosed range for a result-effective variable is routine optimization (In re Aller; In re Antoine). That is the strongest form of the challenge.

Combination C — '554 publication, alone or with '196/'189 (Ground 3)

Motivation: The '554 publication supplies an express genus of cationic lipids suited to component (b) — and the '069 specification itself names '554 as the source for CLinDMA-type cationic lipids. Combining a structurally enabled cationic-lipid disclosure with a particle-architecture disclosure is the classic "two references, one skill set" combination (KSR).

Combination D — Any of the above + '025/'031 publications (methods)

Motivation: The '025 and '031 publications teach formation (continuous mixing / direct dilution) and the 40–150 nm size regime, and are incorporated by reference into the '069 specification itself. This combination is aimed at the dependent claims (size, encapsulation, lipid:nucleic-acid ratio), not at claim 1's novelty.

Overarching motivation argument

(a) The references are all in the same technical field; (b) they address the same known problem; (c) three of four claimed ranges are expressly overlapped, triggering the In re Peterson presumption of obviousness; (d) the fourth window is arithmetically accessible because molar percentages must sum to 100 %; and (e) the specification itself frames the invention as a ratio optimization ("1:57" and "1:62" formulations vs. prior "2:30"/"2:40") — i.e., the patent's own characterization supplies the "design incentive."

5. Why these combinations were held not to render claim 1 obvious

This is not hypothetical: IPR2019-00554 reached a Final Written Decision on July 23, 2020 rejecting all three grounds, and the Federal Circuit affirmed on December 1, 2021. The reasoning breaks the chain at both motivation and reasonable expectation:

1. The presumption never attached. Peterson requires that the prior art actually teach the overlapping range. Because no reference taught any phospholipid range, the overlap had to be manufactured by assumption.
2. The subtraction arithmetic is unsound. The panel called it "an oversimplification based on unfounded assumptions." Working the math in the other direction yields a nonsensical −40 mol % phospholipid minimum or 77.5 mol % maximum — "an amount inconsistent with the teachings of the prior art." Moderna also shifted its own proposed implied range (0–19.5 mol %), undercutting the theory.
3. Interdependence and unpredictability control. Under In re Applied Materials, 692 F.3d 1289, 1298, evidence that components "interacted in an unpredictable or unexpected way could render the combination nonobvious." Arbutus put in "a plethora of evidence" that particle properties "depend on the particle as a whole, rather than on any one component."
4. No result-effective variable / no routine optimization on this record. Even accepting that phospholipid was result-effective, the other three components were also result-effective, and Moderna never "address[ed] the interdependence of the claimed lipid components and how adjustments would affect the nucleic acid-lipid particle as a whole." A related Arbutus filing made the same point against a prima facie-only theory, invoking duPont v. Synvina ("disclosure of very broad ranges may not invite routine optimization") and In re Stepan (motivation to combine with expectation of success is always required).

Objective indicia cutting the other way. The specification reports unexpected results with a real nexus to the claimed windows: the "1:57 SNALP" was "more than 10 times as efficacious as compared to a nucleic acid-lipid particle previously described ('2:30 SNALP') in mediating target gene silencing at a 10-fold lower dose," and the 1:57 and 1:62 formulations were characterized as providing "improved efficacy and tolerability in vivo." Tolerability (liver enzymes, platelets, body weight) is measured in Example-level data at the claimed ratios. That is the Graham factor a challenger must overcome — not merely rebut.

6. What a stronger future § 103 challenge would need

Because the § 103 record is now largely foreclosed as to the references already adjudicated (a D. Del. filing in this dispute asserts the '069 patent has been "dropped" from the district-court case, and the earlier-generated section flags the same absence), the productive attack vectors are different in kind:

1. A single-reference species attack. The better theory is not overlapping ranges but In re Petering/In re Wertheim: find one prior-art composition that literally falls within all four windows simultaneously — e.g., a disclosed or exemplified formulation with ~50–65 mol % cationic lipid, 4–10 mol % phospholipid, 30–40 mol % cholesterol, 0.5–2 mol % PEG-lipid, plus a nucleic acid. Range claims read on disclosed species. Notably, in the parallel '127-patent litigation the Federal Circuit applied exactly this rule — "When a patent claims a chemical composition in terms of ranges and a single prior art reference discloses a composition that falls within each of the ranges, the range is anticipated" — and invalidated ratio claims 10–12. The '069's four-window intersection is narrow but not empty; the specification's own Table 2 shows many in-window formulations, and any pre-priority publication of an equivalent particle is fatal.
2. An express phospholipid range in prior art. The entire nonobviousness holding rests on the absence of an express phospholipid disclosure. A § 102(a)/§ 102(b) reference stating, e.g., "phospholipid 5–15 mol %" in an SNALP would restore the Peterson presumption across all four components.
3. Enablement/possession-style art from the same lab, or intervening publications showing the phospholipid window was a recognized, directional, result-effective variable (i.e., evidence of which way to move it and why).
4. § 112 rather than § 103. Moderna's live district-court theory targets enablement (In re Wands; Amgen v. Sanofi) — that LNP patents with pDNA/siRNA examples do not enable the full scoped genus including mRNA. That is an independent vulnerability the § 103 history does not touch.

7. Bottom line

On the record actually developed, the § 103 combinations do not invalidate claim 1 of US 8,058,069. The best combinations — (1) WO 2005/007196 + US 2006/0134189; (2) those two plus Lin and Ahmad as routine-optimization teachings; and (3) US 2006/0240554 alone or in combination — each fail at the same single element: no reference expressly teaches a phospholipid content of 4–10 mol %, and the inference by subtraction is defeated by evidence that the four lipid components are interdependent and interact unpredictably. That conclusion was reached by the PTAB (FWD, July 23, 2020) and affirmed by the Federal Circuit in ModernaTX, Inc. v. Arbutus Biopharma Corp., No. 20-2329 (Fed. Cir. Dec. 1, 2021). The claim's durability rests on a narrow, species-rich window plus demonstrated unexpected efficacy and tolerability, not on any structural novelty in the lipid chemistry.

What I could not verify with high confidence, stated explicitly: (i) the full bibliographic identities of "Lin" and "Ahmad" (the opinion's footnotes 1–2 would supply them; I did not retrieve those footnotes); (ii) the complete "References Cited" table as rendered on the Google Patents page; and (iii) the verbatim text of claims 2–22 of the granted patent, which I have not read directly — my descriptions of the dependent claims remain inferential, per the prior section's caveat.

Primary sources: https://patents.google.com/patent/US8058069B2/en · https://cases.justia.com/federal/appellate-courts/cafc/20-2329/20-2329-2021-12-01.pdf · https://www.winston.com/print/v2/content/[1047815](/patent/1047815)/moderna-has-standing-to-appeal-because-of-risk-of-infringement-suit-but-ptabs-rejection-of-modernas-invalidity-arguments-is-affirmed.pdf · https://www.lexology.com/library/detail.aspx?g=2080aef3-87b7-4d6e-abcf-6f44444fc46a · https://ptacts.uspto.gov/ptacts/public-informations/petitions/[1522819](/patent/1522819)/ (IPR2019-00554 papers)